AI Article Synopsis
- The understanding of haematological malignancies is advancing thanks to genetic research, culminating in the publication of the 5th Edition of the WHO Classification of Haematolymphoid Tumours in 2022.
- The full version of this classification, known as the "Blue Book," will be available in print in early 2024 and can be accessed online.
- This special issue of Medizinische Genetik explores the genetic changes that are crucial for classifying haematolymphoid neoplasms according to WHO-HAEM5 and their importance for diagnosing different blood cancers.
Article Abstract
The landscape of haematological malignancies is constantly evolving, driven by advances in our understanding of their genetic basis. This has cumulated within the 5 Edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours published in short form in 2022 [1, 2] and being available in full length both as "Blue Book" (in print expected early 2024) as well as web-based classification (see: https://tumourclassification.iarc.who.int/welcome/). Similarly, the importance of genetic alterations for the classification is highlighted in other classification systems related to haematologic neoplasms [3-5]. In this special issue of the Medizinische Genetik, we present a comprehensive overview of the genetic alterations contributing to the classification of haematolymphoid neoplasms in the 5 Edition of the WHO classification (WHO-HAEM5) and its diagnostic relevance in the context of various haematological malignancies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11006249 | PMC |
| http://dx.doi.org/10.1515/medgen-2024-2008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!